Trevi Therapeutics Inc — Balance Sheet (NASDAQ:TRVI) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 47.13 M38.48 M123.02 M89.4 M110.9 M193.44 M Total liabilities 19.65 M21.4 M15.56 M6.86 M11.26 M10.2 M Total equity 27.28 M17.07 M107.46 M82.55 M99.64 M183.24 M Total liabilities & shareholders' equities 47.13 M38.48 M123.02 M89.4 M110.9 M193.44 M Total debt 13.95 M14.48 M9.15 M——— Net debt -31.05 M-22.34 M-111.36 M———

News

Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript

Zacks.com featured highlights include Trevi, Metalla Royalty & Streaming and Vermilion

Trevi Therapeutics stock gets Oppenheimer nod on Phase 3 plans

Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in March

Trevi plans two phase 3 trials for chronic cough treatment in IPF

Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect?

Trevi’s nalbuphine ER shows significant reduction in IPF cough

Trevi Therapeutics schedules FDA meeting for chronic cough program

Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Canadian Solar (NASDAQ:CSIQ), Elme (NYSE:ELME)

Trevi Therapeutics stock price target raised to $18 by Stifel on cough drug potential

Trevi Therapeutics stock hits all-time high of 14.01 USD

Trevi Therapeutics appoints David Hastings as new CFO